CSL (ASX:CSL) share price edges lower on annual R&D update

The CSL Limited (ASX:CSL) share price is on the move on Tuesday after the release of its R&D update for 2020…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price is on the move this morning following the release of its research and development (R&D) investor briefing.

At the time of writing, the biotherapeutics company's shares are down 0.3% to $303.15.

What was in the update?

This morning CSL released a comprehensive update on all its R&D activities. This includes its work across a number of programs to prevent and treat COVID-19 such as UQ/CSL V451 and AZD1222.

UQ/CSL V451 is a recombinant virus spike protein (molecular clamp technology) formulated with MF59 adjuvant under a partnership with the University of Queensland and the Coalition for Epidemic Preparedness Innovations (CEPI). Phase 1 trials are ongoing, with phase 2 and 3 trials expected in December if everything goes to plan.

AZD1222 is an adenovirus vector designed to express spike protein of COVID-19 virus in situ. It has partnered with AstraZeneca on this one. It is currently undergoing phase 3 trials.

What else did CSL talk about?

CSL revealed that its AEGIS-II Phase 3 study of CSL112 (ApoA-1) for the treatment of acute coronary syndrome has now resumed following a COVID-19 related pause.

More than 10,000 people have been enrolled to date. It is aiming to launch the product in 2023-2025.

Management also spoke about the results of its Phase 2 clinical trials of Garadacimab, a treatment in hereditary angioedema (HAE).

It advised that Garadacimab met its primary end points, with a statistically significant reduction in HAE attacks. It also sees opportunities for the therapy in the treatment of fibrotic disease, cardiovascular disease, and inflammatory disease.

Finally, another topic of interest was the aquisition of Clazakizumab (CSL300) earlier this year. It is an anti-interleukin-6 monoclonal antibody being used in the IMAGINE Phase 3 trial for the treatment of chronic active antibody-mediated rejection. This is the leading cause of long-term rejection in kidney transplant recipients.

In June, Goldman Sachs estimated that Clazakizumab, if successful, could generate peak non-risk adjusted sales of US$5.4 billion by FY 2032 and risk adjusted sales of US$1.3 billion.

Based on trials to date, management appears optimistic that the therapy could improve outcomes for transplant recipients.

Foolish Takeaway.

Overall, based on this pipeline, CSL appears well-placed to both save lives and generate strong returns for investors over the 2020s.

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A male electricity worker in hard hat and high visibility vest stands underneath large electricity generation towers as he holds a laptop computer and gazes up at the high voltage wires overhead.
Share Market News

ASX 200 utilities shares outperform: Are investors switching to defensives?

The utilities sector was the best performing sector by a wide margin last week.

Read more »

A couple cheers as they sit on their lounge looking at their laptop and reading about the rising Redbubble share price
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

two men smiling with a laptop in front of them, symbolising a rising share price.
Broker Notes

These ASX 200 shares could rise 25% to 60%

Analysts think these shares are top buys and could rise materially.

Read more »

A man looking at his laptop and thinking.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors finished the trading week on a sour note today.

Read more »

Happy teen friends jumping in front of a wall.
Share Gainers

4 ASX 200 stocks smashing the benchmark this week

Investors are sending these four ASX 200 stocks soaring this week. But why?

Read more »

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Broker Notes

Bell Potter says this growing ASX 200 stock can rise over 40%

Big returns could be on the cards for buyers of this stock.

Read more »

Broker written in white with a man drawing a yellow underline.
Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A couple makes silly chip moustache faces and take a selfie on their phone.
Share Market News

Which delivered superior returns in FY25: CSL, A2 Milk, or Telstra shares?

We review the share price growth and dividend income delivered to investors in FY25.

Read more »